

Michigan Pharmacy and Therapeutics Committee
Meeting of June 5, 2007
DRAFT Minutes DRAFT

Introductions and Approval of Minutes of March 6, 2007 Meeting

Dr. Nedd introduced Paul Reinhart, Medicaid Director, who thanked the Committee for the work it does on behalf of the State and demonstrated how management of the Preferred Drug List has significantly impacted on Michigan's ability to control pharmaceutical costs and save tax dollars.

The minutes of the March 6, 2007 meeting were approved.

Dean VanLoo, PharmD, was not able to attend this meeting. He was on a work assignment out of state for his employer. The other members of the Committee were present.

Presentation of Web PA by First Health Services Corporation

Annette Paul, RPh, presented a demonstration of how prescribers can use a secure website to obtain real time prior authorizations(PA) of pharmaceuticals for those drugs on the Michigan Pharmaceutical Product List (MPPL) that have PA requirements. Interested persons can go to the website, www.Michigan.fhsc.com to obtain more information

New Drugs

Invega: the Committee recommended the Department add this drug to the MPPL,
Tykerb:, the Committee recommended the Department add this drug to the MPPL
Tyzeka: the Committee recommended the Department add this drug to the MPPL

Line Extensions

Symbicort: The Committee recommended the Department add this drug to the MPPL and to the PDL in the class "Beta Adrenergic/Corticosteroid Inhaler Combinations"

Allegra suspension: the Committee recommended the Department add this to the MPPL and to the PDL class, "Antihistamines-2nd Generation" with PA, but allow prescriptions at point of sale analogous to Zyrtec liquid.

Olux-E foam: the Committee recommended adding to the MPPL with PA

Desonate Gel: the Committee recommended adding to the MPPL with PA

Pulmicort flexhalers: the Committee recommended adding this to the MPPL and to the PDL in the class "Inhaled Glucocorticoids" without PA

Orapred ODT: the Committee recommended adding to the MPPL with PA

Lialda: the Committee recommended adding this to the MPPL without PA

Review of PDL Classes

Following review and discussion, the Committee recommended the following:

Antibiotics-Anti-Infectives

Antifungals-Onychomycosis

No change to the current listings

Antifungals-Oral

No change to the current listings

Antivirals-Herpes

No change to the current listings

Antivirals-Influenza

No change to the current listings

Cephalosporin 1st, 2nd 3rd generation

No change to the current listings

Hepatitis C

No change to the current listings

Add HCV genotype 1 virus infection as part of PA criteria for exceptions

Change weight criteria to BMI based as is used in other drug reviews

Ketolides

No change to current listing

Macrolides

Add prior authorization to Zmax

No change to other listings

Quinolones

No change to current listings

In addition, at the request of the Department, the workgroup reviewed otic quinolone products to create a new PDL class. The Committee recommends to the Department the following new class:

“Otic Quinolones

Ciprodex, Floxin available without prior authorization

CiproHC available with prior authorization”

Asthma-Allergy

Inhaled Anticholinergics

Add Atrovent and Atrovent HFA to medications available without PA

Antihistamines

No changes to current classification

Beta Adrenergics –Short Acting

Add Ventolin HFA without prior authorization

Add Proair and Proventil HFA with prior authorization

Change Xopenex HFA to requiring prior authorization

Beta Adrenergics-Long Acting

Remove prior authorization from Foradil

Add Brovana without prior authorization when the six month timeframe has elapsed for new drug introduction

Beta Adrenergics for Nebulizers

No changes to current classification

Beta Adrenergic/Corticosteroid Inhaler Combinations

Add Symbicort without prior authorization

Inhaled Glucocorticoids

No changes to current classification

Leukotriene Inhibitors

No changes to current classification

Nasal Steroids

Add Flonase without prior authorization

Add prior authorization to fluticasone

Public Comment

The following persons made comment to the Committee

R. Mack, Sepracor, Brovana

Dr. Smith, Takeda, diabetes products

Lisa Goetz, PharmD, Proctor and Gamble, Actonel

G. Anderson, PhD, AstraZeneca, Nexium

J. Strezewski, PharmD, TAP, Prevacid

S. Greenstein, PhD, Boehringer Ingelheim, Flomax

S. Ryu, PharmD, Amgen, Enbrel

J. Anema, MD, Pfizer, Detrol LA

B. Facca, PharmD, GSK, Avandia, Avandamet, Avandaryl, Imitrex, Vesicare

Dr. R. Cole, Roche, Boniva

S. Robinson, RPh, Amylin, Byetta

G. Katz, MD, Alcon, Travatan Z, Pataday, Vigamox

R. Rood, MD, Lilly, analog insulins

M. DiFiore, Stiefel Labs, Duac

L. Katz, PharmD, Sanofi-Aventis, Lantus, Apidra

Following Public Comment the Committee discussed having the presenters, at their option, submit short summaries of the presentations for Committee review prior to the meeting at which these drug products will be taken up. Such short documents can be submitted by e-mail to perrig@Michigan.gov, for distribution to the other members

Next Meeting

Scheduled for Tuesday, September 11, 2007 at Kellogg Center